Tango Therapeutics, Inc.
TNGX
주식 순위
#4537
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
주가
$27.18
마지막 동기화: 2026-07-31
시가총액
$3.38B
변동 (1일)
-1.41%
변동 (1년)
197.05%
국가
US
거래 Tango Therapeutics, Inc. (TNGX)
카테고리
Healthcare
Tango Therapeutics, Inc. (TNGX)의 EPS
June 2026 기준 EPS TTM: $-0.85
Tango Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-0.85입니다. 2023년 말에는 회사의 EPS가 $-1.08였으며, 이는 2022년의 EPS $-1.23와 감소입니다.
Tango Therapeutics, Inc.의 EPS 기록 (2019 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-0.85 | -28.57% |
| 2024 | $-1.19 | 10.19% |
| 2023 | $-1.08 | -12.20% |
| 2022 | $-1.23 | 30.85% |
| 2021 | $-0.94 | -41.98% |
| 2020 | $-1.62 | 3.18% |
| 2019 | $-1.57 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -2,137.65% |
US
|
|
| $-7.98 | 838.82% |
US
|
|
| $-5.29 | 522.35% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,363.53% |
NL
|
